Zenicor Medical Systems AB (ZENI) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Zenicor Medical Systems AB SEK 0.15, price SEK 0.93, upside -83.6%, quality 17 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Zenicor Medical Systems AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Zenicor Medical Systems AB (publ), a medical technology company, provides products and solutions for the diagnosis of arrhythmia and stroke prevention.
Show more
Zenicor Medical Systems AB (publ), a medical technology company, provides products and solutions for the diagnosis of arrhythmia and stroke prevention. The company offers Zenicor One, a handheld ECG device for arrhythmia; Zenicor Flex, a device that provides ECG data and arrhythmia detection; and Zenicor View, a web-based system solution for all types of arrhythmia investigations. It also provides Zenicor Direct, a solution with interpretation services and services for device logistics. The company was incorporated in 2003 and is headquartered in Stockholm, Sweden.
Stock analysis
Zenicor Medical Systems AB (ZENI) currently trades at kr 0.9300, while our model-based Fair Value estimate is kr 0.1530, implying the stock looks roughly 507.9% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of kr 1.46 per share, and 5 of the 14 models we run sit above the kr 0.9300 price.
Bear case: the Earnings-Based group reads lowest at kr 0.0800, and 9 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: kr 0.1190 (bear) to kr 0.1955 (bull), the price of kr 0.9300 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 17/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Zenicor Medical Systems AB reported revenue of 27.9M SEK in FY2025 versus 19.7M SEK in FY2021, a compound +9.2%/yr. Reported net income was 214K SEK in FY2025, compounding −23.6%/yr from FY2021.
Key figures
Market cap 24.4M SEK (≈ $2.5M) · P/E ratio 13.3 · P/S ratio 0.10 · EPS (TTM) kr 0.0700 · Net margin 0.8% · Return on equity 2.0% · Return on assets (EBIT) −0.5% · Operating margin 6.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 63% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −84%, ZENI screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (kr 0.0800 to kr 3.42). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear kr 0.1190Fair Value kr 0.1530Bull kr 0.1955
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (kr 0.0514 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.41/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+10.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.3%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−44.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−44.8%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 8%
Compare Zenicor Medical Systems AB with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score17 · Bottom 25%
Fair Value upside−83% · Bottom 25%
Profitability
Return on equity (TTM)2% · Above median
Return on assets2% · Above median
Net margin (TTM)3% · Below median
Operating margin (TTM)6% · Above median
Growth and dividend
Revenue growth10% · Above median
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (TTM)13.3× · Cheapest 25%
P/S (TTM)0.07× · Cheapest 25%
EV/EBITDA1.1× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 10
FUTURE (revenue growth)48· sector 31
PAST (return on equity)8· sector 7
HEALTH (low debt)94· sector 97
DIVIDEND (yield)0· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Zenicor Medical Systems AB Fair Value". https://www.fairvalue-calculator.com/stock/ZENI
Frequently asked questions
Is Zenicor Medical Systems AB (ZENI) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 0.1530 versus a price of kr 0.9300, about −84% upside (overvalued).
What is the fair value of ZENI?
Our model-based fair value for Zenicor Medical Systems AB is kr 0.1530 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 0.9300.
What is the quality score of ZENI?
Zenicor Medical Systems AB has a Quality Score of 17/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zenicor Medical Systems AB (ZENI)?
Our model-based price target is the fair value of kr 0.1530 (as of Sep 24, 2026) from 14 valuation models. Cautious scenario kr 0.1190, optimistic scenario kr 0.1955. It is a calculation from audited fundamentals, not an analyst target.
What is the Zenicor Medical Systems AB stock forecast for 2026?
Our models put fair value at kr 0.1530, about −84% upside versus a price of kr 0.9300 (overvalued). Cautious scenario kr 0.1190, optimistic scenario kr 0.1955. The calculation is refreshed regularly with new filings.
What is the revenue of Zenicor Medical Systems AB (ZENI)?
Zenicor Medical Systems AB reported trailing-twelve-month revenue of about 32.9M SEK (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Zenicor Medical Systems AB (ZENI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zenicor Medical Systems AB it is kr 0.1530 per share (as of Sep 24, 2026), against a price of kr 0.9300. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Zenicor Medical Systems AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ZENI trades above its calculated fair value: price kr 0.9300, fair value kr 0.1530, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ZENI?
No. The price is what the market pays today (kr 0.9300); the fair value is what the company's own numbers justify (kr 0.1530). For Zenicor Medical Systems AB the two are kr 0.7770 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zenicor Medical Systems AB worth?
The market values Zenicor Medical Systems AB at about 24.4M SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 0.9300; our models calculate a fair value of kr 0.1530 per share.
What do the bullish and bearish scenarios say about ZENI?
Our models span a range for Zenicor Medical Systems AB: cautious scenario kr 0.1190, base kr 0.1530, optimistic kr 0.1955 per share (as of Sep 24, 2026, price kr 0.9300). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ZENI?
Zenicor Medical Systems AB trades at a price-to-earnings ratio of 13.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 0.1530 is built from several models across several years. Other multiples: P/S 0.1, EV/EBITDA 1.1.
How solid is the balance sheet of Zenicor Medical Systems AB (ZENI)?
Balance-sheet figures for Zenicor Medical Systems AB (as of Sep 24, 2026): return on equity 2.0%, debt of 0.12 per unit of equity. They feed the Quality Score of 17/100, which measures business quality independently of the share price.
How far is ZENI from its 52-week high?
Zenicor Medical Systems AB trades at kr 0.9300, about 63% below its 52-week high of kr 2.48 and 6% above the low of kr 0.8800 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.1530 is for.
Which stocks are comparable to Zenicor Medical Systems AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zenicor Medical Systems AB stock attractive at the current price?
The data as of Sep 24, 2026: price kr 0.9300, calculated fair value kr 0.1530 (−84%), Quality Score 17/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ZENI calculated?
We run Zenicor Medical Systems AB through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.1530, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Zenicor Medical Systems AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zenicor Medical Systems AB (ZENI)?
The closing price on Sep 24, 2026 was kr 0.9300. Our model-based fair value is kr 0.1530, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zenicor Medical Systems AB right now?
The price sits above even our optimistic bull case (kr 0.1955). The favourable scenario is already priced in. Weak quality (17/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Zenicor Medical Systems AB
How large is the market capitalisation of Zenicor Medical Systems AB (ZENI)?
The market capitalisation of Zenicor Medical Systems AB is 24.4M SEK (≈ $2.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zenicor Medical Systems AB (ZENI)?
The price-to-sales ratio of Zenicor Medical Systems AB is 0.10 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zenicor Medical Systems AB (ZENI)?
Earnings per share at Zenicor Medical Systems AB are kr 0.0700 (price ÷ EPS = P/E 13.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Zenicor Medical Systems AB (ZENI)?
The net margin of Zenicor Medical Systems AB is 0.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zenicor Medical Systems AB (ZENI)?
The return on equity (ROE) of Zenicor Medical Systems AB is 2.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zenicor Medical Systems AB (ZENI)?
On an EBIT basis the return on assets of Zenicor Medical Systems AB is −0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zenicor Medical Systems AB (ZENI)?
The operating margin of Zenicor Medical Systems AB is 6.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zenicor Medical Systems AB (ZENI)?
Revenue at Zenicor Medical Systems AB is growing +9.6% versus a year earlier (3y avg +9.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zenicor Medical Systems AB (ZENI)?
Earnings per share at Zenicor Medical Systems AB are growing −19.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zenicor Medical Systems AB (ZENI) generate?
The free cash flow of Zenicor Medical Systems AB is −15.0M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Zenicor Medical Systems AB (ZENI) carry?
The net debt of Zenicor Medical Systems AB is 7.2M SEK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Zenicor Medical Systems AB in the live analysis
One click puts Zenicor Medical Systems AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
